Catalent, a drug, biologics and consumer health products maker, along with members of its board of directors, were hit with a shareholder derivative lawsuit Sept. 5 in federal court in New Jersey.

The suit alleged that the company made false and misleading statements causing the stock price to soar to record highs and then plummet.